Search

Edwards Lifesciences Corp

Abierto

SectorSanidad

87.01 1.6

Resumen

Variación precio

24h

Actual

Mínimo

84.8

Máximo

86.14

Métricas clave

By Trading Economics

Ingresos

290M

381M

Ventas

92M

1.7B

P/B

Media del Sector

49.429

64.641

BPA

0.78

Margen de beneficios

23.092

Empleados

16,000

EBITDA

20M

520M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+19.96% upside

Dividendos

By Acuity

Próximas Ganancias

29 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.1B

48B

Apertura anterior

85.41

Cierre anterior

87.01

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

54 / 340 Clasificación en Healthcare

Edwards Lifesciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2026, 23:46 UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

28 jul 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 jul 2026, 19:41 UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 jul 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 jul 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 jul 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 jul 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 jul 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Comparación entre iguales

Cambio de precio

Edwards Lifesciences Corp previsión

Precio Objetivo

By TipRanks

19.96% repunte

Estimación a 12 Meses

Media 102.88 USD  19.96%

Máximo 110 USD

Mínimo 85 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Edwards Lifesciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

16

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

54 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat